[시장보고서]인플루엔자 치료제 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

인플루엔자 치료제 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Influenza Medication Market (Product: Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

상품코드 : 1420995

리서치사 : Transparency Market Research

발행일 : 2023년 12월

페이지 정보 : 영문 159 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 7,945,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,058,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 16,172,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

인플루엔자 치료제 시장 - 리포트의 범위

세계의 인플루엔자 치료제 시장에 관한 TMR의 리포트는 과거와 현재의 성장 동향 및 2023-2031년의 예측 기간 중 시장 지표의 귀중한 인사이트를 얻을 기회를 연구하고 있습니다. 이 리포트는 세계의 인플루엔자 치료제 시장 매출을 제공하고, 2017-2031년의 기간, 2023년을 기준년, 2031년을 예측년으로 간주합니다. 이 리포트는 2023-2031년 세계의 인플루엔자 치료제 시장의 연평균 성장률(CAGR %)도 제공합니다.

이 리포트는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 시행되고, 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 제조업체와 인터뷰를 시행했습니다. 2차 조사에는 인플루엔자 치료제 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차보고서, 프레스 릴리스 및 관련 문서의 참조가 포함됩니다.

시장 스냅숏
2023년 시장 가치	9억 700만 달러
2031년 시장 가치	11억 달러
CAGR	2.2%

이 리포트는 세계의 인플루엔자 치료제 시장의 경쟁 구도를 상세히 파악하고 있습니다. 세계의 인플루엔자 치료제 시장에서 활동하는 주요 기업이 식별되고, 각각의 기업이 다양한 속성의 관점으로부터 프로파일링되고 있습니다. 회사 개요, 재무 상황, 최근 동향, SWOT는 이 리포트에서 소개되고 있는 세계의 인플루엔자 치료제 시장 기업의 속성입니다.

시장 기업 - 경쟁 매트릭스(기업의 계층 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
- F. Hoffmann-La Roche Ltd.,
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH
- Sun Pharmaceutical Industries Ltd.
- Mylan, Inc.
- GlaxoSmithKline plc
- Daiichi Sankyo Company
- Natco Pharma

KSA

영문 목차

영문목차

Influenza Medication Market - Scope of Report

TMR's report on the global influenza medication market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global influenza medication market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global influenza medication market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the influenza medication market.

Market Snapshot
Market Value in 2023	US$ 907 Mn
Market Value in 2031	US$ 1.1 Bn
CAGR	2.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global influenza medication market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global influenza medication market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global influenza medication market.

The report delves into the competitive landscape of the global influenza medication market. Key players operating in the global influenza medication market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global influenza medication market profiled in this report.

Key Questions Answered in Global influenza medication Market Report:

What is the sales/revenue generated by influenza medication across all regions during the forecast period?
What are the opportunities in the global influenza medication market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Influenza Medication Market - Research Objectives and Research Approach

The comprehensive report on the global influenza medication market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global influenza medication market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global influenza medication market.

1. Executive Summary

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Influenza Medication Market

4. Market Overview

4.1. Market Segmentation
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Influenza Medication Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry

6. Influenza Medication Market Analysis and Forecast, by Product Type

6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017-2031
- 6.3.1. Zanamivir
- 6.3.2. Oseltamivir
- 6.3.3. Peramivir
- 6.3.4. Amantadine
- 6.3.5. Rimantadine
- 6.3.6. Inosine
- 6.3.7. Others (Laninamivir Octanoate, etc.)
6.4. Market Attractiveness, by Product Type

7. Global Influenza Medication Market Analysis and Forecast, by Distribution Channel

7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2023-2031
- 7.3.1. Hospitals
- 7.3.2. Clinics
- 7.3.3. Pharmacies
- 7.3.4. Others
7.4. Market Attractiveness, by Distribution Channel

8. Global Influenza Medication Market Analysis and Forecast, by Region

8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

9. North America Influenza Medication Market Analysis and Forecast

9.1. Introduction
- 9.1.1. Key Findings
9.2. Market Value Forecast, by Product Type, 2017-2031
- 9.2.1. Zanamivir
- 9.2.2. Oseltamivir
- 9.2.3. Peramivir
- 9.2.4. Amantadine
- 9.2.5. Rimantadine
- 9.2.6. Inosine
- 9.2.7. Others (Laninamivir Octanoate, etc.)
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 9.3.1. Hospitals
- 9.3.2. Clinics
- 9.3.3. Pharmacies
- 9.3.4. Others
9.4. Market Value Forecast, by Country, 2017-2031
- 9.4.1. U.S.
- 9.4.2. Canada
9.5. Market Attractiveness Analysis
- 9.5.1. By Product Type
- 9.5.2. By Distribution Channel
- 9.5.3. By Country

10. Europe Influenza Medication Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2017-2031
- 10.2.1. Zanamivir
- 10.2.2. Oseltamivir
- 10.2.3. Peramivir
- 10.2.4. Amantadine
- 10.2.5. Rimantadine
- 10.2.6. Inosine
- 10.2.7. Others (Laninamivir Octanoate, etc.)
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.3.1. Hospitals
- 10.3.2. Clinics
- 10.3.3. Pharmacies
- 10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Italy
- 10.4.5. Spain
- 10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
- 10.5.1. By Product Type
- 10.5.2. By Distribution Channel
- 10.5.3. By Country/Sub-region

11. Asia Pacific Influenza Medication Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017-2031
- 11.2.1. Zanamivir
- 11.2.2. Oseltamivir
- 11.2.3. Peramivir
- 11.2.4. Amantadine
- 11.2.5. Rimantadine
- 11.2.6. Inosine
- 11.2.7. Others (Laninamivir Octanoate, etc.)
11.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.3.1. Hospitals
- 11.3.2. Clinics
- 11.3.3. Pharmacies
- 11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.4.1. China
- 11.4.2. Japan
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
- 11.5.1. By Product Type
- 11.5.2. By Distribution Channel
- 11.5.3. By Country/Sub-region

12. Latin America Influenza Medication Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017-2031
- 12.2.1. Zanamivir
- 12.2.2. Oseltamivir
- 12.2.3. Peramivir
- 12.2.4. Amantadine
- 12.2.5. Rimantadine
- 12.2.6. Inosine
- 12.2.7. Others (Laninamivir Octanoate, etc.)
12.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.3.1. Hospitals
- 12.3.2. Clinics
- 12.3.3. Pharmacies
- 12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
- 12.5.1. By Product Type
- 12.5.2. By Distribution Channel
- 12.5.3. By Country/Sub-region

13. Middle East & Africa Influenza Medication Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017-2031
- 13.2.1. Zanamivir
- 13.2.2. Oseltamivir
- 13.2.3. Peramivir
- 13.2.4. Amantadine
- 13.2.5. Rimantadine
- 13.2.6. Inosine
- 13.2.7. Others (Laninamivir Octanoate, etc.)
13.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.3.1. Hospitals
- 13.3.2. Clinics
- 13.3.3. Pharmacies
- 13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
- 13.5.1. By Product Type
- 13.5.2. By Distribution Channel
- 13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
- 14.3.1. F. Hoffmann-La Roche Ltd.,
  - 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.1.2. Product Portfolio
  - 14.3.1.3. Financial Overview
  - 14.3.1.4. SWOT Analysis
  - 14.3.1.5. Strategic Overview
- 14.3.2. Teva Pharmaceutical Industries Ltd.
  - 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.2.2. Product Portfolio
  - 14.3.2.3. Financial Overview
  - 14.3.2.4. SWOT Analysis
  - 14.3.2.5. Strategic Overview
- 14.3.3. Sandoz International GmbH
  - 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.3.2. Product Portfolio
  - 14.3.3.3. Financial Overview
  - 14.3.3.4. SWOT Analysis
  - 14.3.3.5. Strategic Overview
- 14.3.4. Sun Pharmaceutical Industries Ltd.
  - 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.4.2. Product Portfolio
  - 14.3.4.3. Financial Overview
  - 14.3.4.4. SWOT Analysis
  - 14.3.4.5. Strategic Overview
- 14.3.5. Mylan, Inc.
  - 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.5.2. Product Portfolio
  - 14.3.5.3. Financial Overview
  - 14.3.5.4. SWOT Analysis
  - 14.3.5.5. Strategic Overview
- 14.3.6. GlaxoSmithKline plc
  - 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.6.2. Product Portfolio
  - 14.3.6.3. Financial Overview
  - 14.3.6.4. SWOT Analysis
  - 14.3.6.5. Strategic Overview
- 14.3.7. Daiichi Sankyo Company
  - 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.7.2. Product Portfolio
  - 14.3.7.3. Financial Overview
  - 14.3.7.4. SWOT Analysis
  - 14.3.7.5. Strategic Overview
- 14.3.8. Natco Pharma
  - 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 14.3.8.2. Product Portfolio
  - 14.3.8.3. Financial Overview
  - 14.3.8.4. SWOT Analysis
  - 14.3.8.5. Strategic Overview

한글목차

인플루엔자 치료제 시장 - 리포트의 범위

목차

제1장 주요 요약

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 시장 분석과 예측 : 제품 유형별

제7장 세계 시장의 분석과 예측 : 유통 채널별

제8장 세계 시장의 분석과 예측 : 지역별

제9장 북미 시장 분석과 예측

제10장 유럽 시장 분석과 예측

제11장 아시아태평양 시장 분석과 예측

제12장 라틴아메리카 시장 분석과 예측

제13장 중동 및 아프리카 시장 분석과 예측

제14장 경쟁 구도